Skip to main content
Smart Investors Daily
Integra LifeSciences Holdings Corporation logo

NASDAQ · IART

Integra LifeSciences Holdings Corporation

Healthcare · Medical - Devices

$13.98

Down-$0.42 (-2.92%)

Updated Nov 17, 2026, 5:18 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.1B
P/E ratio
-2.18
Dividend yield
0.00%
52-week range
$8.70 – $20.49
Volume
706.39K
Avg. volume
1.05M

Price performance · IART

IART price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

IART closed at $13.98 after 21 trading sessions, up 3.94% for the selected period.

Last close
$13.98
Period change
+3.94%
Period low
$11.84
Period high
$14.82
Daily close
View OHLC price history
IART OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$14.30$14.52$13.94$13.98706.39K
Nov 13, 2026$14.42$14.62$14.15$14.40648.84K
Nov 12, 2026$14.62$14.93$14.125$14.351.07M
Nov 11, 2026$14.55$15.07$14.37$14.771M
Nov 10, 2026$14.37$14.76$13.78$14.531.77M
Nov 9, 2026$13.66$14.40$13.417$14.371.04M
Nov 6, 2026$13.94$14.125$13.315$13.42871.89K
Nov 5, 2026$14.87$15.25$13.73$14.12992.07K
Nov 4, 2026$13.97$15.15$13.84$14.821.17M
Nov 3, 2026$13.69$13.79$13.40$13.631.69M
Nov 2, 2026$12.98$13.97$12.98$13.611.51M
Oct 30, 2026$12.75$12.86$12.3338$12.751.04M
Oct 29, 2026$12.43$13.005$12.28$12.831.19M
Oct 28, 2026$11.98$12.33$11.93$12.241.79M
Oct 27, 2026$12.25$12.25$11.72$11.991.43M
Oct 26, 2026$12.05$12.24$12.00$12.10916.43K
Oct 23, 2026$12.12$12.396$11.815$11.911.21M
Oct 22, 2026$11.69$12.36$11.66$12.3251.39M
Oct 21, 2026$12.77$13.745$11.57$11.842.02M
Oct 20, 2026$13.51$13.76$13.27$13.331.31M
Oct 19, 2026$13.13$13.49$13.1113$13.45726.14K

Latest IART news

The latest Smart Investors Daily articles mentioning IART.

IART research

Overview

Company profile and research snapshot.

Company profile

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
IART recent ratings
DateFirmRatingTarget
Oct 27, 2026UBSNeutral—
Oct 26, 2026Truist SecuritiesHold—
Oct 22, 2026JP MorganUnderweight—
Oct 22, 2026CitizensMarket Outperform—
Oct 22, 2026Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Integra LifeSciences (IART) Stock Could Be A Bargain Based On Cash Flow

Integra LifeSciences Holdings has seen a sharp reset in recent years, yet the shares have climbed back to US$14.12, which raises a clear question about what its cash flows really support today. After such a mixed share price path, investors are increasingly asking whether the current valuation is still grounded in the money the business can generate over time. Over the past 5 years the stock has fallen 79.3%. This puts the focus squarely on whether the current US$14.12 price is now aligned...

Yahoo · Nov 6, 2026

Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference

PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 2:45 p.m. ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciences Integra LifeScience

Yahoo · Nov 5, 2026

What Integra LifeSciences Doubters Got Wrong

If Integra LifeSciences was on your watchlist instead of in your portfolio, the past year probably felt expensive to sit out. Investors who held Integra LifeSciences over the past year are up 30.0%, including dividends. That outcome invites a harder question. Back on 4 November 2025, could an investor reasonably have spotted that aging-driven demand in neurosurgery and advanced wound care might outweigh the visible regulatory and reimbursement risks? A Narrative on Simply Wall St is one...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.